Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  V. Pawar,et al.  Cost-Effectiveness Of Posaconazole Versus Fluconazole Or Itraconazole In The Prevention Of Invasive Fungal Infections Among Neutropenic Patients In The United States , 2013 .

[3]  A. Imhof,et al.  Cost-Effectiveness of Posaconazole Compared with Standard Azole Therapy for Prevention of Invasive Fungal Infections in Patients at High Risk in Switzerland , 2010, Oncology.

[4]  Anna García-Altés,et al.  Spanish recommendations on economic evaluation of health technologies , 2010, The European Journal of Health Economics.

[5]  M. Weinstein,et al.  Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[7]  D. Kaul,et al.  Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  J. Jansen,et al.  Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands , 2008, European journal of haematology.

[9]  F. Meunier,et al.  The First European Conference on Infections in Leukaemia - ECIL1: a current perspective. , 2008, European journal of cancer.

[10]  Judy L. Smith,et al.  Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[11]  H. Eraksoy,et al.  The clinical and pharmacoeconomic analysis of invasive aspergillosis in adult patients with haematological diseases , 2008, Mycoses.

[12]  Raoul Herbrecht,et al.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  E. Anaissie,et al.  Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: counterpoint. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  L. Leibovici,et al.  Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Jansen,et al.  Economic Evaluation of Posaconazole Versus Standard Azole Prophylaxis in High Risk Neutropenic Patients in The Netherlands. , 2007 .

[16]  E. Thiel,et al.  Cost-Benefit Assessment of Antifungal Prophylaxis with Liposomal Amphotericin B in Neutropenic Patients , 2007, Oncology Research and Treatment.

[17]  A. Safdar.  Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies. , 2007, The oncologist.

[18]  J. Wingard,et al.  Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[19]  C. Lass‐Flörl,et al.  Primary antifungal prophylaxis in leukaemia patients , 2007 .

[20]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[21]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[22]  N. Brown,et al.  Invasive fungal infections: a review of epidemiology and management options. , 2006, Journal of medical microbiology.

[23]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[24]  T. Walsh,et al.  Epidemiology, Outcomes, and Costs of Invasive Aspergillosis in Immunocompromised Children in the United States, 2000 , 2006, Pediatrics.

[25]  E. Estey,et al.  Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome , 2006, Cancer.

[26]  J. M. Nicolás-Arfelis,et al.  Clinical Use and Tolerability of Voriconazole in the Treatment of Fungal Infections in Critically Ill Patients , 2005, Journal of chemotherapy.

[27]  A. Favero,et al.  Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients. , 2005, The Journal of antimicrobial chemotherapy.

[28]  P. Olaechea,et al.  Economic Impact of Candida Colonization and Candida Infection in the Critically Ill Patient , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[29]  Panagiotis Mavros,et al.  Burden of hospitalization of patients with Candida and Aspergillus infections in Australia. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  Shane Gillespie,et al.  Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  J. L. Pinto,et al.  [What is an efficient health technology in Spain?]. , 2002, Gaceta sanitaria.

[32]  J. A. Sacristán,et al.  Qué es una tecnología sanitaria eficiente en España , 2002 .

[33]  E. Bow,et al.  Antifungal prophylaxis for severely neutropenic chemotherapy recipients , 2002, Cancer.

[34]  J. Meis,et al.  Prophylaxis and treatment of fungal infections associated with haematological malignancies. , 2000, International journal of antimicrobial agents.

[35]  E. Anaissie,et al.  Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[37]  L. Jong‐van den Berg,et al.  Cost Effectiveness of Itraconazole in the Prophylaxis of Invasive Fungal Infections , 2012, PharmacoEconomics.

[38]  Sebastian Schneeweiss,et al.  European Healthcare Policies for Controlling Drug Expenditure , 2012, PharmacoEconomics.

[39]  L. Scott,et al.  Posaconazole , 2012, Drugs.

[40]  M F Drummond,et al.  Economic evaluation. , 2006, Singapore medical journal.

[41]  M. Marín-Casino,et al.  [Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis]. , 2005, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[42]  J. Antonio,et al.  Evaluación económica del uso de voriconazol versus anfotericina B en el tratamiento de la aspergilosis invasiva , 2005 .